|
AstraZeneca is proud to be a diamond sponsor for the 34th ECCMID Congress. We eagerly anticipate your participation in Barcelona or online through the ECCMID integrated platform! |
Saturday 27 April 2024 I 12:15-13:15 (CEST) I Hall L |
Despite vaccination, certain patient populations remain at a heightened risk of severe COVID-19 outcomes. Join our expert-led session to delve into key data and discuss the continued importance of recognising and responding to COVID-19 risk in immunocompromised populations. |
Yoav Keynan, |
Marta Boffito, |
Paul Loubet, |
Sunday 28 April 2024 I 10:30-10:50 (CEST) I Innovation and Pipeline Theatre |
Roger Paredes, MD, PhD Head of Department of Infectious Diseases, Hospital Germans Trias, Barcelona, Spain |
Building on the symposium discussion, Dr Paredes will explore the ongoing burden of COVID-19 and the potential
for targeted prevention strategies in immunocompromised patient populations. Don't miss this opportunity to be part of the discussion! |
|
Monday 29 April 2024 I 10:30-10:50 (CEST) I Innovation and Pipeline Theatre |
Rosalind Hollingsworth, PhD Global Medical Affairs Head, Vaccines and Immune Therapies, AstraZeneca, US |
Consider how innovations in vaccines and monoclonal antibodies are evolving to offer a complementary approach to protection from infectious diseases. | |
Learn more about AstraZeneca's commitment to reducing the global burden of infectious diseases through the development of transformative technologies. |
These are non-promotional sessions organised and funded by AstraZeneca. The information displayed during the meeting is exclusively for healthcare professionals empowered to prescribe or dispense medicinal products. Please do not distribute in media, supporting materials or communication channels aimed at the general public. La información mostrada durante la reunión está dirigida exclusivamente a Profesionales Sanitarios facultados para prescribir o dispensar medicamentos. Por favor no distribuir en medios, soportes o canales de comunicación dirigidos a público general. |
Vault ID: Z4-63606; Date of approval: April 2024.
©2024 AstraZeneca Global UK. 1 Francis Crick Avenue, All rights reserved. |
|